Imuldosa (Ustekinumab)

Ustekinumab binds to the p40 subunit shared by interleukin‑12 and interleukin‑23, preventing these cytokines from activating their receptors on immune cells. This blocks the downstream Th1 and Th17 inflammatory pathways, reducing the production of pro‑inflammatory mediators that contribute to skin, joint, and intestinal inflammation.

The dosing regimen for Imuldosa is determined individually by a qualified prescriber based on the patient’s condition, weight, and clinical response. Healthcare professionals follow the approved prescribing information to select the appropriate dose and administration schedule.

Safety data for ustekinumab in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting therapy.

To request Imuldosa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Imuldosa (ustekinumab) belongs to the interleukin‑12/23 inhibitor class, whereas many other biologics target tumor necrosis factor‑α or interleukin‑17 pathways. Ustekinumab typically has a longer dosing interval after the initial loading phase and a safety profile that emphasizes infection monitoring, offering an alternative for patients who may not respond to or tolerate other biologic classes.

Imuldosa should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the container. Maintaining the cold‑chain ensures the medication retains its potency and safety.

Imuldosa is given by subcutaneous injection. The initial dose is usually administered in a healthcare setting, followed by subsequent injections according to the prescriber’s schedule, which may be every 8 or 12 weeks after the loading phase. Patients should be trained on proper injection technique if self‑administration is planned.

The most serious risks include the development of serious infections such as tuberculosis, opportunistic fungal or viral infections, and rare cases of malignancy. Patients should be monitored for signs of infection, and any unexplained fever, cough, or weight loss should be promptly evaluated by a healthcare professional.

Imuldosa is contraindicated in individuals with known hypersensitivity to ustekinumab or any of its excipients. It should also be avoided in patients with active, uncontrolled infections, including active tuberculosis, and in those receiving live vaccines. A thorough medical assessment is required before initiating therapy.